MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Key facts

Sponsor

Masonic Cancer Center, University of Minnesota

Intervention

Pembrolizumab(drug)

Enrollment

28 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2027

Study locations (1)

• Masonic Cancer Center, Minneapolis, Minnesota, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07275216
  Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
  City of Hope Medical Center
• RECRUITINGPHASE2NCT07209059
  PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
  National Research Center for Hematology, Russia
• RECRUITINGPHASE2NCT06984146
  Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
  National Medical Research Radiological Centre of the Ministry of Health of Russia
• RECRUITINGPHASE2NCT06745076
  Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
  University of Washington
• RECRUITINGPHASE1, PHASE2NCT06642792
  A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
  Akeso
• RECRUITINGPHASE2NCT07234487
  Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
  St. Petersburg State Pavlov Medical University
• RECRUITINGPHASE2NCT06812858
  PD-1 Inhibitors Maintenance for cHL Post-autoHCT
  St. Petersburg State Pavlov Medical University
• RECRUITINGPHASE4NCT06831370
  A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
  Takeda

See all trials for Classic Hodgkin lymphoma →